The first describes a 56-year-old man with metastasized lung adenocarcinoma who was eligible for targeted therapy due to EGFR exon 19 deletion and therefore received combination therapy of 80 mg Osimertinib with 7.4 GBq [177Lu]Lu-FAP-2286 [62]. This evidence concerns the gene FAP and lung adenocarcinoma.